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Summary
Disorders of cutaneous repair can cause disability or death
given that skin functions as a protective barrier against the
external environment. The inflammatory response triggered
by tissue damage is thought to play both positive (e.g., path-
ogen-killing) and negative (e.g., scarring) roles in repair
[1–3]. Inflammatory resolution mediators such as chem-
erin15 (C15) control the magnitude and duration of the
inflammatory response; however, their role in wound repair
and scarring is unknown [4–8]. Here, we show that the C15
precursor, chemerin, and its receptor, ChemR23, are both
upregulated after skin damage and that the receptor is ex-
pressed by macrophages, neutrophils, and keratinocytes.
Dynamic live-imaging studies of murine cutaneous wounds
demonstrate that C15 delivery dampens the immediate intra-
vascular inflammatory events, including platelet adhesion to
neutrophils, an important event in driving leukocyte recruit-
ment. C15 administration indirectly accelerates wound
closure while altering fibroblast-mediated collagen deposi-
tion and alignment to reduce scarring. Macrophage recruit-
ment is restricted to the immediate wound site rather than
spilling extensively into the adjacent tissue as in control
wounds, andmacrophage phenotype in C15-treated wounds
is skewed toward a less inflammatory phenotype with
reduced iNOS, increased Arginase-1, and lower wound
tumor necrosis factor a (TNF-a) expression. Modulation of
inflammatory resolution pathways in acute and chronic
wounds may therefore provide a novel therapeutic avenue
to improve repair and reduce scarring.Results
Repair of adult cutaneous wounds is a complex process that
restores cellular structures and tissue layers but culminates
in a scar consisting of linear bundles of collagen as opposed*Correspondence: jenna.cash@bristol.ac.uk (J.L.C.), paul.martin@bristol.
ac.uk (P.M.)
This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/3.0/).to the more randomly oriented collagen bundles found in
normal skin. Wound repair in embryos involves very little
inflammation and scar-free healing, suggesting that inflam-
matory cells are causally involved in scarring [1, 2, 9]. Resolu-
tion mediators function to dampen the inflammatory response
and promote its resolution [5, 10]; however, their potential role
in the context of dermal wound repair has, surprisingly, barely
been investigated. Studies have shown that mice lacking the
resolution mediator annexin A1 suffer delayed wound closure
[11] and that proresolving mediators, including resolvin E1
(RvE1), promote corneal re-epithelialization and organ regen-
eration [12, 13].
The anti-inflammatory and proresolving peptide chemerin15
(C15) is a 15 aa peptide derived from cleavage of chemerin,
which promotes phagocytosis of microbes and inhibits heart
damage after myocardial infarction in a mouse model [6–8].
Full-length chemerin is a proinflammatory protein that can be
cleaved to generate antimicrobial peptides and anti-inflam-
matory species [8, 14, 15]. C15 acts through the G-protein
coupled receptor ChemR23, expressed on macrophages and
neutrophils [6, 16]. ChemR23 is a multifunctional receptor
that transduces the anti-inflammatory and proresolving effects
of C-terminal chemerin peptides, including C15 and the lipid
RvE1, as well as the proinflammatory effects of full-length
chemerin [17–19]. The aim of this study was to determine
what role C15might play in regulating the wound inflammatory
response and how thismight influence subsequent skin repair.
Chemerin and ChemR23 Expression during Wound
Healing
Our full-thickness 4 mm excisional wounding model involves
the complete removal of the epidermis, dermis, and pannicu-
lus carnosus, which is firmly adherent to the base of the
dermis. Healing commences after the formation of a fibrin
clot that is invaded by granulation tissue and by the migration
of an epidermal tongue along the interface between the gran-
ulation tissue and the clot (schematic in Figure 1A).
We found few chemerin+ (C15 precursor) cells in unwounded
skin, but their numbers increased profoundly in granulation
tissue—they peaked at days 1 and 4 after wounding before
declining to negligible numbers by day 7 (Figure 1B). Macro-
phages, but not neutrophils, were found to be chemerin+ (Fig-
ure S1, available online). ChemR23 was upregulated 10-fold in
granulation tissue by day 1 and remained high until day 7
(Figure 1B); it was expressed by wound macrophages, neu-
trophils, and keratinocytes, but not fibroblasts (Figure S1).
C15 Improves the Rate and Quality of Wound Repair
To investigate the potential effect of the chemerin peptide C15
on wound repair, we administered peptide (100 pg/wound) or
vehicle control in Pluronic gel immediately after wounding.
Macroscopic analysis showed that wound closure was
markedly accelerated at all stages of repair in C15-treated
wounds (Figures 1C and 1D; Figure S1) with a corresponding
reduction in granulation tissue (Figure 1E). Maximal differ-
ences in wound areas were observed 4 days after wounding
(C15: 36% 6 5% versus vehicle; 70% 6 6% of starting wound
size; Figure 1D). We also noted that C15 treatment resulted in
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Figure 1. Skin Wound Healing Is Accelerated with C15 Treatment through Direct and Indirect Mechanisms
Four 4 mm excisional wounds were made to the dorsal skin of Sv129Ev mice. Vehicle or C15 (100 pg/wound) in 30% Pluronic gel was administered directly
into the wound immediately after wounding.
(A) Schematic diagrams illustrating the location of skin wounds and measurements derived from histological sections.
(legend continued on next page)
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1408significantly earlier scab loss—58%of wounds lost their scabs
by day 7 in comparison to only 17% of vehicle-treated wounds
(Figure 1F). These differences suggest that C15 promotes
faster wound re-epithelialization, which may be directly by
affecting keratinocyte migration and/or indirectly by modu-
lating fibroblast behavior and leading to accelerated wound
contraction. Indeed, epithelial gaps (schematic in Figure 1A)
constituted only 4% of the width of day 4 C15-treated wounds
in comparison to 60% of vehicle-treated wounds; however,
epithelial tongues were only fractionally longer (Figures 1G
and 1H), suggesting that quicker re-epithelialization is largely
a consequence of a reduced denuded area available for re-
epithelialization. Indeed, aSMA staining for contractile myofi-
broblasts (Figure 1I) indicated that day 4 C15-treated wounds
possessed higher levels of these contractile cells than did
control wounds. Interestingly, ChemR232/2mice showed ele-
vated neutrophil recruitment, but no significant changes in
wound re-epithelialization or closure (Figure S2).
C15 Exerts Direct and Indirect Effects on Keratinocyte
and Fibroblast Physiology
While our studies demonstrate that C15 can promote wound
re-epithelialization and closure, it is unclear whether this is
mediated entirely through C15’s effects on inflammation or
whether there might be some direct modulation of keratino-
cyte and fibroblast behavior by the peptide. We found that
C15 modestly promoted keratinocyte migration into an
in vitro ‘‘scratch wound’’ with optimal doses of 10–100 pM.
(Figure 1J). However, C15 had no effect on fibroblast-medi-
ated collagen gel contraction (Figure 1K). These data suggest
that the accelerated wound closure observed in C15-treated
wounds is via indirect mechanisms, whereas accelerated
re-epithelialization could, in part, be through direct effects of
C15 on keratinocytes.
C15 Regulates Neutrophil and Platelet Behavior
Immediately after Wounding
Wound repair from the late stages of fetal development on-
ward is accompanied by robust recruitment of inflammatory
cells (neutrophils and monocytes) to the wound [20]. The
optimal balance between sufficient leukocyte recruitment to
combat any invading microorganisms and excessive patho-
logical inflammation that contributes to scarring is clearly of
critical importance in any tissue-repair response or therapeu-
tic treatment [2, 20].
Platelets are essential for primary hemostasis, but they
are also important amplifiers of acute inflammation. Activated
platelets can trigger neutrophil recruitment by directly
interacting with neutrophils to prompt a process called(B) Immunohistochemical staining during the wound repair time course reveale
wounding, particularly in granulation tissue.
(C) Macroscopic photos of vehicle- and C15-treated wounds 0–14 days after w
(D) Wound area relative to initial wound area at days 1, 4, and 7 after woundin
(E) Granulation tissue area at wound midpoints.
(F) Scab loss 7 days after wounding.
(G) Representative photos of sections from day 4 wound midpoints stained w
(H) Re-epithelialization quantified by measurement of the length of wound epi
(I) aSMA myofibroblasts in day 4 wounds.
(J) HaCaTs (human keratinocytes) were allowed to migrate for 15 hr to fill in a ‘‘s
(K) Murine dermal fibroblasts were suspended in a collagen I and media mixtur
allowed to solidify at 37C, and gel contraction was assessed 24 and 48 hr lat
Data are expressed as means 6 SEM; there were six to ten mice (D and F) or fo
experiments (J and K). *p < 0.05, **p < 0.01, and ***p < 0.001 relative to vehicle-t
field of view.‘‘secondary’’ neutrophil capture [21–23]. Platelets have previ-
ously been shown to express ChemR23 and respond to the
ChemR23 lipid ligand RvE1 [24, 25], but the potential role of
C15 in platelet biology has not been tested.
The standard excisional wound model described above is
not amenable to live imaging of the dynamics of wound
leukocyte and platelet behavior. To visualize the immediate
inflammatory events occurring after cutaneous wounding, we
used fluorescence spinning-disk intravital microscopy of
small cutaneous burn wounds treated with vehicle or C15
(schematics in Figures 2A and 2B [26]).
At 2 hr after wounding, the first neutrophils were seen
entering the wound, and the majority were found 150–500 mm
from the edge of the burn. Even at this early stage, the effects
of C15 were clear: we observed a 68% reduction in neutrophil
numbers both within the wound and in the surrounding area
(up to 500 mm; Figures 2C and 2D). Sham-operated animals ex-
hibited low levels of neutrophil-endothelial cell interactions
(Figures 2E and 2F), platelet-endothelial cell interactions
(Figure 2G), and neutrophil-platelet interactions (Figure 2H).
However, tissue injury elicited marked platelet and neutrophil
rolling and adhesion within nearby postcapillary venules.
Treatment with C15 significantly blunted these inflammatory
responses. Specifically, 2 hr after burning, neutrophil adhe-
sion was reduced by 74% (Figure 2F), platelet adhesion and
rolling were inhibited by 76% and 62%, respectively (Fig-
ure 2G), and the percentage of neutrophils interacting with
platelets dropped by 49% (Figure 2H; see also Movies S1,
S2, and S3).
C15 Restricts Leukocyte Recruitment and Modulates
Macrophage Phenotype during Repair
In the excisional wounding model, we monitored leukocyte
recruitment dynamics during the repair period. C15 admin-
istration inhibited neutrophil recruitment to excisional
cutaneous wounds by up to 60% on day 1 (50% on day 4; Fig-
ure 3A), but no changes in mast cell numbers were observed
(Figure 3B). C15 reduced monocyte-macrophage recruitment
on day 1 by 40%, but by day 7, there appeared to be no signif-
icant difference in the numbers of F4/80+ cells at the wound
site (Figure 3C). However, more careful spatial analysis
revealed a markedly different macrophage distribution in the
immediately adjacent unwounded tissue (Figure 3D). Unlike
vehicle-treated day 7 wounds, in which F4/80+ cells were
abundant up to 3,000 mm from the wound edge, C15-treated
wounds showed restricted monocyte-macrophage recruit-
ment to the wound site such that macrophages extended
only 356 6 108 mm into the adjacent tissue (Figures 3D–3F).
This suggests that C15 may function to prevent excessived increases in the number of cells expressing chemerin and ChemR23 after
ounding.
g.
ith haematoxylin and eosin.
thelial gaps and tongues on days 1, 4, and 7 after wounding.
cratch wound’’ in vitro in the presence of C15 (1–1,000 pM) or media control.
e supplemented with 10–1,000 pM C15 or vehicle (media) control. Gels were
er.
ur to eight wounds (B, E, H, and I) per treatment group or four independent
reated controls. See also Figure S1. The following abbreviation is used: FOV,
A B C D
E F
G H
Figure 2. C15 Inhibits Early Platelet and Neutrophil Inflammatory Events after Cutaneous Wounding
A single 580 6 39 mm2 focal injury was induced on the surface of a dorsal skin flap with a modified electrocautery device. C15 (100 pg/wound) or vehicle
(saline) was administered intradermally immediately after wounding. For sham experiments, mice were prepared for intravital microscopy and imaged
identically to injured animals, but no injury was induced.
(A) Schematic diagram of the skin preparation with burn injury for multichannel fluorescence spinning-disk confocal microscopy.
(B) Schematic showing the wound as viewed with a 43 objective; necrotic cells stained with propidium iodide are shown in red.
(C) Low-power (43) views of necrotic cells (propidium iodide, red) and neutrophil recruitment (blue) to vehicle- or C15-treated wounds 2 hr after injury. The
scale bar indicates 150 mm. Dotted lines indicate the wound margin, 150 mm and 500 mm from the wound edge.
(D) Quantification of neutrophil recruitment to wounds treated with vehicle or C15.
(E) High-power (20x) views of neutrophil (Ly6G, blue) and platelet (CD49b, red) behavior within dermal postcapillary venules 2 hr after wounding. The scale
bar indicates 30 mm. The arrow in ‘‘Sham’’ indicates a rolling neutrophil. The large arrow in ‘‘Burn + vehicle’’ indicates a neutrophil without interacting plate-
lets. The small arrow indicates neutrophils with interacting platelets.
(F–H) Quantification of neutrophil rolling and adhesion (F), platelet rolling and adhesion (G), and platelet-neutrophil interactions (H) after wounding.
Data are expressed as means6 SEM; four to eight vessels were visualized per time point in each mouse, and there were four to eight animals per treatment
group. Vehicle (n = 4), burn (n = 8), C15 (n = 7). *p < 0.05, **p < 0.01, and ***p < 0.001 relative to vehicle-treated mice. See also Movies S1, S2, and S3. The
following abbreviation is used: FOV, field of view.
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1409macrophage recruitment, which could be detrimental to the
wound repair process, and to direct macrophages to leave
the wound earlier. Indeed, by day 14, markedly fewer F4/80+
cells were detectable at the wound site. This may be of signif-
icant potential therapeutic benefit since spreading of the in-
flammatory response beyond the immediate wound site may
lead to excessive scarring, as seen in extreme cases with
keloid scars [27].
We also noted that a high proportion of vehicle-treated
wound macrophages exhibited a round morphology, whereas
C15-treated wound macrophages had many protrusions,
which may reflect a more migratory or phagocytic phenotype
(Figure 3F). Indeed, C15-treated wounds exhibited higher
levels of Prussian blue+ iron-loaded cells (macrophages with
phagocytosed erythrocytes) at days 4 and 7 after wounding,
and these cells appeared to track away from the wound
(Figure 3G). Increased wound haem clearance could aidrepair by removing a known stimulus of ‘‘M1’’ macrophage
activation, which has previously been associated with poor
repair in iron-burdened chronic wounds [28]. Analysis of tumor
necrosis factor a (TNF-a) expression revealed markedly lower
levels within the wound granulation tissue after C15 treatment,
suggestive of a less inflamed environment (Figure 3H). More-
over, phenotypic analysis of wound macrophages showed
that more macrophages in C15-treated wounds expressed
Arginase-1, typically associated with an ‘‘M2’’ phenotype,
and fewer expressed iNOS, typically associated with an
‘‘M1’’ phenotype, although no change in the ‘‘M2 marker’’
Ym1 was observed (Figure 3I).
Collectively, these data indicate that C15 administration not
only acts to restrict inflammatory cell recruitment to the wound
site but may also direct earlier resolution and skew macro-
phage phenotype toward that typically linked with improved
wound repair.
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Figure 3. C15 Dampens Wound Leukocyte Recruitment and Skews Macrophage Phenotype
Four 4 mm excisional wounds were made to the dorsal skin of Sv129Ev mice. Vehicle or C15 (100 pg/wound) in 30% Pluronic gel was administered directly
into the wound immediately after wounding.
(A–C) Representative micrographs and quantification of neutrophil (Ly6G+ cell, brown) (A), mast cell (toluidine blue+ cell, blue) (B), and monocyte-macro-
phage (F4/80+ cell, brown) (C) recruitment to wound granulation tissue up to 14 days after wounding.
(legend continued on next page)
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1411C15 Inhibits Scarring by Modifying Collagen Organization
within the Healing Wound
Collagen is a major structural component of normal skin, and
prior to wounding, it exhibits a basketweave appearance in
the dermis, whereas after healing, collagen is thought to be
deposited in aligned bundles characteristic of a scar. The de-
gree of scarring has previously been assessed either by mea-
surement of collagen levels within the wound or by subjective
measurement of collagen fiber orientation [29, 30].
To better assess collagen fiber orientation, we designed a
novel algorithm to quantify collagen fiber alignment within
wounded versus unwounded dermis (Figure S3). As expected,
unwounded skin displayed abundant collagen with a basket-
weave appearance (largely randomly oriented fibers) with a
low alignment (0.576 0.003; Figures 4A–4C). In vehicle-treated
day 7wounds, collagenwas laid down in amore linear fashion,
resulting in a high alignment of 0.90 6 0.01. Wound treatment
with C15, however, resulted in collagen deposition with amore
random collagen fiber orientation closer to unwounded dermal
collagen organization, which equated to reduced alignment in
comparison to that of vehicle-treated wounded skin (C15:
0.716 0.02; Figures 4A–4C). The data obtained from our align-
ment algorithm compare favorably with those of an estab-
lished technique for assessing collagen quantity by viewing
wounds stained with picrosirius red under polarized light (Fig-
ure S3) and suggest that a downstream consequence of C15
treatment appears to be a reduction in the degree of scarring
at repair sites.
Discussion
Various genetic and pharmacological approaches for knock-
ing down the wound inflammatory response have suggested
that leukocytes deliver signals that lead to scarring [2, 31].
Clearly, genetic deletion of immune cells is not a practical
clinical option to control scarring; however, since resolution
mediators drive the cessation of the inflammatory response,
they may provide therapeutic targets for modulating wound
inflammation in an attempt to regulate the repair and scarring
process [10, 32].
In this study, we assessed the impact of a proresolving
mediator on dermal wound repair and scarring. By adminis-
tering the anti-inflammatory and proresolving peptide C15 to
wounds, we were able to speed up wound closure, re-epithe-
lialization, and scab loss while suppressing wound neutrophil
and macrophage recruitment and limiting scarring. C15 most
likely achieves these effects through direct modulation of
leukocyte dynamics at the wound site since our previous
studies have demonstrated that C15 can suppress activation
of integrins required to mediate neutrophil adhesion and
transendothelial migration [6]. This may, in part, be the mech-
anism underpinning our observed reduction in neutrophil
recruitment to excisional wounds (Figure 3A) and dampened
neutrophil-endothelial and neutrophil-platelet interactions at(D) Macrophage immunostaining through the midpoint of day 7 wounds. R
macrophage-dense area.
(E) Quantification of the distance that macrophages extend beyond the wound
(F) Schematic showing macrophage distribution around vehicle- and C15-trea
(G) Quantification and representative photos of Prussian blue+ iron-loaded cel
(H) Quantification and representative photos of TNF-a expression (brown).
(I) Characterization ofmacrophage phenotypewithin day 7C15- and vehicle-tre
marker.
Data are expressed as means6 SEM; there were four to eight wounds per treat
following abbreviation is used: FOV, field of view.burn lesions (Figure 2). Similar observations have been made
by others with the resolution mediator resolvin D2 [33].
Furthermore, C15 stimulates a switch of macrophage pheno-
type to cells expressing M2-like markers, including arginase
1, and reduced expression of M1 markers, including iNOS
and TNF-a. The resolution mediators RvE1 and maresin have
also recently been shown to be capable of switching macro-
phage phenotype, suggesting that a defining characteristic
of proresolvingmediatorsmay be their ability to switchmacro-
phage phenotype [34].
C15 does not promote wound closure by directly regulating
fibroblast physiology but rather does so through indirect
actions. We postulate that leukocytes exposed to C15 in the
wound bed signal to fibroblasts either through a soluble medi-
ator or via cell-cell contacts to promote conversion to contrac-
tile myofibroblasts and thus faster contraction of the wound.
In addition, we suggest a role for C15 in regulating platelet
behavior at the site of tissue damage. Platelets play a plethora
of roles in physiology, but a definitive role in wound repair has
yet to be established. It is known that platelets drive wound
neutrophil and macrophage recruitment and secrete trans-
forming growth factor b (TGF-b), and thus it would be tempting
to assume that since wound leukocyte recruitment and TGF-b
drive scarring, platelets, by proxy,might contribute to scarring.
Our live-imagingstudies indicate thatonestepwhere thismight
be driven is by platelet ‘‘capturing’’ of neutrophils in vessels
near the wound and that C15 treatment inhibits this process.
Although it has been known for some time that collagen in
scars exhibits a linear, bundled arrangementwhile unwounded
skin exhibits a looser, basketweave appearance, very little is
known about the dynamics of collagen deposition in wounds
and how the behavior of fibroblasts is altered to lead to these
very different patterns of collagen deposition. What is clear is
that signals from inflammatory cells at the wound site directly
influence these fibroblast behaviors, and thus by modulating
the wound inflammatory response, it is possible to dramati-
cally modulate the scarring phenotype. This, to a large degree,
is what we have achieved through application of C15. A next
step will clearly be to investigate further how immune cells
change fibroblast behaviors because this will provide further
therapeutic targets for blocking scarring downstream of
immune regulators.
Although the cellular and molecular mechanisms behind
repair and scar formation have yet to be fully elucidated, this
study suggests that targeting the body’s endogenous resolu-
tion mechanisms could provide a potential therapeutic route
to promote repair and minimize scarring through modulation
of leukocyte and stromal cell physiology.Experimental Procedures
All experiments were conducted with approval from the local ethical review
committee at the University of Bristol and in accordance with the UK Home
Office regulations (Guidance on the Operation of Animals, Scientificed arrows indicate wound edges, and green lines mark the edge of the
margin into the surrounding tissue.
ted day 7 wounds and corresponding photos of macrophage morphology.
ls within the wound.
atedwounds. Ym1 andArg1 areM2markers, and iNOS is anM1macrophage
ment group. *p < 0.05 and **p < 0.01 relative to vehicle-treated wounds. The
AB C
Figure 4. C15 Inhibits Scar Formation
(A) Day 7 wound midsections (43 objective on top; 203 objective on bottom) stained with picrosirius red (collagen) from unwounded skin and vehicle- and
C15-treated wounds.
(B) Images used for algorithm analysis (zoomed-in areas are shown underneath). Red lines were fitted by the algorithm along white lines of collagen, and the
angles of each line were measured and compared for determining fiber alignment.
(C) Quantification of collagen fiber alignment in day 7 and 14 wounds. An entirely randomly oriented network of collagen fibers would score 0.5 in this
analysis, whereas complete fiber alignment would score 1.
Data are expressed as means 6 SEM; there were six wounds per treatment group. ***p < 0.001 and **p < 0.01 relative to vehicle-treated wounds. See also
Figure S3 and Supplemental Experimental Procedures.
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1412Procedures Act, 1986). Wild-type (Sv129Ev) and ChemR232/2 mice were
supplied by Takeda Pharmaceuticals and used for excisional wounding
studies. C57Bl6/J mice were purchased from Jackson Laboratories
(Canada) and used for intravital imaging experiments.
C15
C15 (AGEDPHGYFLPGQFA) was synthesized by Mimotopes, reconstituted
(1 mM in PBS and 0.1% BSA), and stored at 280C for up to 6 months.
Peptide was diluted from fresh aliquots for each experiment.
Excisional Cutaneous Wounding
Mice (7–10 weeks old) were randomly assigned a treatment group and
anaesthetized with isofluorane. Four full-thickness excisional wounds
(4 mm biopsy punch, Kai Industries) were made to the shaved dorsal skin.
Vehicle (PBS) or C15 (100 pg/wound) was delivered topically by pipette
into the wound cavity immediately after wounding (40 ml in a vehicle of
30% Pluronic F-127 gel [is liquid at 4C but solidifies at body temperature];
Sigma Aldrich). Wounds were photographed with an Olympus camera andcalibration card on days 0, 1, 4, 7, and 14 after wounding, and wound areas
were calculated with ImageJ software.
Preparation and Histological Analysis of Excisional Cutaneous
Wounds
Wounds were harvested, prepared, and analyzed essentially as previously
described [35] (for detailed methods, see the Supplemental Experimental
Procedures). Because of the lack of a commercially available anti-
ChemR23 antibody suitable for formalin-fixed, paraffin-embedded immuno-
histochemistry, we immunostained for b-galactosidase (2 mg/ml, Invitrogen)
in Cmklr12/2 LacZ reporter mice to determine the ChemR23 expression
profile.
Intravital Imaging of Cutaneous Focal Necrotic Injury
Skin preparation for intravital microscopy was performed essentially as
previously described [26] (for further detail, see the Supplemental Experi-
mental Procedures)—C15 or vehicle control was administered intradermally
immediately after wounding.
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We designed an algorithm to quantify the level of collagen fiber alignment
within tissue sections stained with picrosirius red. We used 2D fast Fourier
transformations to scan images for nonrandom, noncircular regions and to
measure the angle of fitted ellipses. The algorithm quantified the alignment
of fibers by comparing each angle with every other from an image such that
we gave parallel fibers a score of 1 and perpendicular fibers a score of 0.
Two perpendicular lines have an alignment of 0; therefore, in a random
arrangement, total alignment = 0.5, and in perfectly aligned tissue, align-
ment = 1. We performed the analysis by using our novel algorithm in ImageJ
software and Silverlight software. For further details, see the Supplemental
Experimental Procedures and Figure S3.
Statistical Analysis
Student’s t test and one- and two-way ANOVA with the Bonferroni post hoc
test were performed with GraphPad Prism 5.0 software.
Supplemental Information
Supplemental Information includes three figures, Supplemental Experi-
mental Procedures, three movies, and two Supplemental Algorithms and
can be found with this article online at http://dx.doi.org/10.1016/j.cub.
2014.05.006.
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